Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced the signing of a term sheet to acquire worldwide rights to two differentiated clinical-stage oncology assets from Celyn Therapeutics, Inc. These assets target non-small cell lung cancer (NSCLC) and include CL-273, a pre-IND reversible, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor.
This acquisition aims to expand Kairos Pharma’s oncology pipeline with late-preclinical and Phase 1-ready assets addressing a multi-billion dollar market marked by significant unmet medical needs. CL-273 is designed to broadly inhibit various EGFR mutations prevalent in NSCLC patients, including resistance-associated variants, while sparing wild-type receptors. CL-741 targets the c-MET pathway, a known driver of resistance in EGFR-mutant NSCLC and several other cancers, offering a highly selective therapeutic approach.
John Yu, M.D., CEO of Kairos Pharma, emphasized, “This acquisition strengthens our capabilities to overcome drug resistance in lung cancer by combining targeted therapies against both EGFR and MET pathways. Our clinical consortia at Cedars-Sinai Medical Center facilitates rapid advancement of these compounds into clinical trials.”
The global kinase inhibitor market is valued at approximately 60.7 billion USD in 2025, with EGFR inhibitors accounting for around 32.5%. The targeted NSCLC segment represents a substantial opportunity, particularly in Asian populations where EGFR mutations are more prevalent. CL-273, developed with an AI-driven drug discovery platform, offers a wide safety margin and broad mutation coverage. Meanwhile, CL-741 addresses the rapidly growing c-MET inhibitor market projected to surpass 10 billion USD by 2030.
Clinical data support the dual inhibition strategy, as combination EGFR and MET inhibitor therapy has demonstrated improved progression-free survival in patients with EGFR-mutant, MET-amplified NSCLC.
This strategic partnership with Celyn Therapeutics leverages Kairos Pharma’s operational expertise and clinical infrastructure with innovative drug candidates poised to advance lung cancer treatment.
혁신적 항암 치료제 개발에 주력하는 임상 단계 바이오제약 기업 카이로스 파마(Kairos Pharma, Ltd., 뉴욕증권거래소 아메리칸 KAPA)가 오비메드(OrbiMed)와 토리 파인스 인베스트먼트(Torrey Pines Investment)의 투자를 받은 비상장 바이오테크 기업 셀린 테라퓨틱스(Celyn Therapeutics, Inc.)와 전략적 자산 인수를 위한 텀시트(Term sheet, 주요 조건 합의서)를 체결했다고 발표했다. 제안된 계약 조건에 따라 카이로스 파마는 비소세포폐암(NSCLC)을 표적으로 하는 고도로 차별화된 임상 단계 항암 자산 2건의 전 세계 판권을 인수하게 된다. 대상 자산은 임상시험계획(IND) 제출 전 단계의 가역적·야생형(정상) 보호 범EGFR 억제제 ‘CL-273’과 1상 임상 준비를 마친 경구용 제2b형(Type IIb) c-MET 키나아제 억제제 ‘CL-741’이다.
댓글 없음:
댓글 쓰기